Evaxion Biotech A/S Profit Margin

Evaxion Biotech A/S (EVAX) currently reports a profit margin of -115.59% as of June 2026. That compares with -376.11% in the prior-year period — up 69.3% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Evaxion Biotech A/S's profit margin history and peer comparisons.

Evaxion Biotech A/S's profit margin increased from -376.11% to -115.59% — a 69.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Evaxion Biotech A/S's profit margin of -115.59% is lower than the Healthcare sector average of 21.34%. That is roughly 641.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Evaxion Biotech A/S's current -115.59% should be judged against Healthcare norms (sector average: 21.34%) and against EVAX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -115.59%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Evaxion Biotech A/S, and consider following EVAX for alerts when major investors trade the stock.